Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (3) , 756-763
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
This publication has 21 references indexed in Scilit:
- Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialThe Lancet, 2018
- TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK IIBMC Cancer, 2018
- Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialEuropean Urology, 2018
- Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysisPLOS ONE, 2018
- Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive PatientsClinical Oncology, 2018
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017
- Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal OligometastasesClinical Oncology, 2017
- Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicityPractical Radiation Oncology, 2017
- A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)BMC Cancer, 2016